Skip to main content
. Author manuscript; available in PMC: 2021 Apr 9.
Published in final edited form as: Cell. 2017 Sep 7;170(6):1109–1119.e10. doi: 10.1016/j.cell.2017.08.027

Figure 2. Combination of Talimogene Laherparepvec and Pembrolizumab Is Effective in Patients with Low Tumor CD8+ Density.

Figure 2.

(A) Baseline CD8+ density in tumor biopsies according to response rate. Magnitude of bars indicates baseline tumor CD8+ density in each patient’s baseline biopsy, and best overall response is indicated on x axis and by bar color. Gold, CR; pink, PR; blue, PD.

(B) Baseline PD-L1 by IHC status (1% cutoff) and IFN-γ signature score by NanoString analysis is shown under each patient’s CD8 result. Best overall response per investigator is shown as of cutoff date of August 2016. Abbreviations: CR, complete response; IFN-γ, interferon γ; IHC, immunohistochemistry; NA, result not available; PD, progressive disease; PR, partial response.